Radiopharm Theranostics Limited announced the dosing of the first patient in its Phase 1 clinical trial of RAD 402 for advanced prostate cancer, marking a key clinical milestone. The company is on track to share data from the first two dose levels in the second half of 2026.
Key takeaways
First patient dosed in Phase 1 clinical trial of RAD 402 for advanced prostate cancer.
Trial is designed to study safety, tolerability, distribution, and preliminary clinical activity.
Targets KLK3 and leverages the dual emission of Tb161.
Preclinical data showed strong tumor targeting with minimal bone/marrow uptake.
On track to share data from first two dose levels in 2H 2026.